Iovance Biotherapeutics, Inc. IOVA

What this company does

Its two commercial products are Amtagvi (lifileucel) and Proleukin (aldesleukin), an interleukin-2 product used in the Amtagvi treatment regimen and other applications. To date, more than 1,500 patients have been treated with commercial and investigational TIL cell therapies manufactured using Iovance processes. As of December 31, 2025, it had 975 employees, of whom 775 were engaged in research and development and commercial manufacturing activities and 200 were engaged in general and administrative support activities. The Iovance Cell Therapy Center, in Philadelphia, Pennsylvania, is the first FDA-approved facility to manufacture commercial TIL cell therapy. Iovance Biotherapeutics, Inc. was founded to build upon TIL cell therapy research initially developed at academic research centers, including the National Cancer Institute.

Written from the business description in IOVANCE BIOTHERAPEUTICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.